Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Personalized KSX01-TCRT in Advanced Solid Tumors
NCT06150365Phase 1Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Bone Marrow HSCs, HLA-independent TCR-T, Allogeneic CAR-T
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KSX01 in solid tumor, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Subject safety at 2 years and tumor efficacy at 2 years. Started Nov 2023; status: recruiting.
02
Drugs
KSX01
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06150365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06150365.